PI-RADS v2.1 4类和5类病变假阳性率评估
本研究纳入169例受试者的182个PI-RADS v2.1 4类或5类病变,分析临床显著前列腺癌(CSPC)的假阳性率。结果显示84.6%(154/182)为前列腺癌,73.1%(133/182)为CSPC,26.9%(49/182)为临床不显著前列腺癌(CIPC)或良性病理。多因素分析中,病变同时位于外周带和中央腺体(OR 0.062;p=0.003)及低PSAD(OR 0.34;p=0.012)与CIPC或良性特征相关。
要点
- PI-RADS v2.1 4类或5类病变中73.1%为CSPC,26.9%为CIPC或良性病理。
- 假阳性病例中炎症占44.9%,CIPC占42.9%,BPH结节占8.2%,正常解剖占4.1%。
- 病变同时位于外周带和中央腺体(OR 0.062;p=0.003)及低PSAD(OR 0.34;p=0.012)与CIPC或良性特征相关。
诊断标准与关键数值
- 182个PI-RADS v2.1 4类或5类病变中,84.6%(154/182)为前列腺癌,73.1%(133/182)为CSPC,26.9%(49/182)为CIPC或良性病理。
- 假阳性病例中,炎症占44.9%(22/49),CIPC占42.9%(21/49),BPH结节占8.2%(4/49),正常解剖占4.1%(2/49)。
- 多因素分析:病变同时位于外周带和中央腺体(OR 0.062;p=0.003)及低PSAD(OR 0.34;p=0.012)与CIPC或良性特征相关。
临床应用与阅片要点
- 在解读PI-RADS v2.1 4类或5类病变时,结合PSAD和病变位置(是否同时累及外周带和中央腺体)有助于判断CSPC可能性。
- PI-RADS v2.1 4类或5类病变中约四分之一为CIPC或良性病理,炎症和CIPC是常见假阳性原因。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine the incidence and false-positive rates of clinically significant prostate cancer (CSPC) in prostate imaging reporting and data system (PI-RADS) category 4 and 5 lesions using PI-RADS v2.1.
METHODS: One hundred and eighty-two lesions in 169 subjects with a PI-RADS score of 4 or 5 were included in our study. Lesions with clinically insignificant prostate cancer (CIPC) or benign pathologic findings were reviewed and categorized by a radiologist. The initial comparison of demographic and clinical data was performed by t-test and χ2 test, and then the logistic regression model was used to determine factors associated with CIPC or benign pathological findings.
RESULTS: Of the 182 PI-RADS category 4 and 5 lesions, 84.6% (154/182) were prostate cancer (PCa), 73.1% (133/182) were CSPC, and 26.9% (49/182) were CIPC or benign pathologic findings. The false-positive cases included 44.9% (22/49) with inflammation, 42.9% (21/49) with CIPC, 8.2% (4/49) with BPH nodules and 4.1% (2/49) with normal anatomy cases. In multivariate analysis, factors associated with CIPC or benign features included those in both the peripheral zone (PZ) and central gland (CG) (odds ratio [OR] 0.062; p = 0.003) and a low prostate-specific antigen density (PSAD) (OR 0.34; p = 0.012).
CONCLUSION: The integration of clinical information (PSAD and lesion location) into mpMRI to identify lesions helps with obtaining a clinically significant diagnosis and decision-making.
引用
- Wang X, Liu W, Lei Y, et al. Assessment of prostate imaging reporting and data system version 2.1 false-positive category 4 and 5 lesions in clinically significant prostate cancer. Abdom Radiol (NY). 2021. PMID: 33710384. doi:10.1007/s00261-021-03023-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。